Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein

被引:155
|
作者
Deml, L
Bojak, A
Steck, S
Graf, M
Wild, J
Schirmbeck, R
Wolf, H
Wagner, R
机构
[1] Univ Regensburg, Inst Med Microbiol, D-93053 Regensburg, Germany
[2] Univ Ulm, Inst Med Microbiol & Immunol, D-89069 Ulm, Germany
关键词
D O I
10.1128/JVI.75.22.10991-11001.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have analyzed the influence of codon usage modifications on the expression levels and immunogenicity of DNA vaccines, encoding the human immunodeficiency virus type 1 (HIV-1) group-specific antigen (Gag). In the presence of Rev, an expression vector containing the Mid-type (wt) gag gene flanked by essential cis-acting sites such as the 5'-untranslated region and 3'-Rev response element supported substantial Gag protein expression and secretion in human H1299 and monkey COS-7 cells. However, only weak Gag production was observed from the murine muscle cell line C2C12. In contrast, optimization of the Gag coding sequence to that of highly expressed mammalian genes (syngag) resulted in an obvious increase in the G+C content and a Rev-independent expression and secretion of Gag in all tested mammalian cell lines, including murine C2C12 muscle cells. Mice immunized intramuscularly with the syngag plasmid showed Th1-driven humoral and cellular responses that were substantially higher than those obtained after injection of the Rev-dependent wild-type (wt) gag vector system. In contrast, intradermal immunization of both wt gag and syngag vector systems with the particle gun induced a Th2-biased antibody response and no cytotoxic T lymphocytes. Deletion analysis demonstrated that the CpG motifs generated within syngag by codon optimization do not contribute significantly to the high immunogenicity of the syngag plasmid. Moreover, low doses of coadministered stimulatory phosphorothioate oligodeoxynucleotides (ODNs) had only a weak effect on antibody production, whereas at higher doses immunostimulatory and nonstimulatory ODNs showed a dose-dependent suppression of humoral responses. These results suggest that increased Gag expression, rather than modulation of CpG-driven vector immunity, is responsible for the enhanced immunogenicity of the syngag DNA vaccine.
引用
收藏
页码:10991 / 11001
页数:11
相关论文
共 50 条
  • [1] Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA Vaccines
    Kong, WP
    Huang, Y
    Yang, ZY
    Chakrabarti, BK
    Moodie, Z
    Nabel, GJ
    JOURNAL OF VIROLOGY, 2003, 77 (23) : 12764 - 12772
  • [2] Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses
    Qiu, JT
    Song, RJ
    Dettenhofer, M
    Tian, CJ
    August, T
    Felber, BK
    Pavlakis, GN
    Yu, XF
    JOURNAL OF VIROLOGY, 1999, 73 (11) : 9145 - 9152
  • [3] Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 gag-derived vaccines in mice
    Wong, SBJ
    Siliciano, RF
    JOURNAL OF VIROLOGY, 2005, 79 (03) : 1701 - 1712
  • [4] Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene
    zur Megede, J
    Chen, MC
    Doe, B
    Schaefer, M
    Greer, CE
    Selby, M
    Otten, GR
    Barnett, SW
    JOURNAL OF VIROLOGY, 2000, 74 (06) : 2628 - 2635
  • [5] Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus
    Ternette, Nicola
    Tippler, Bettina
    Ueberla, Klaus
    Grunwald, Thomas
    VACCINE, 2007, 25 (41) : 7271 - 7279
  • [6] Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA Vaccines
    Megede, JZ
    Otten, GR
    Doe, B
    Liu, H
    Leung, L
    Ulmer, JB
    Donnelly, JJ
    Barnett, SW
    JOURNAL OF VIROLOGY, 2003, 77 (11) : 6197 - 6207
  • [7] DNA vaccines against human immunodeficiency virus type 1
    Estcourt, MJ
    McMichael, AJ
    Hanke, T
    IMMUNOLOGICAL REVIEWS, 2004, 199 (01) : 144 - 155
  • [8] Impact of codon usage modification on T cell immunogenicity and longevity of HIV-1 gag-specific DNA vaccines
    Bojak, A
    Wild, J
    Deml, L
    Wagner, R
    INTERVIROLOGY, 2002, 45 (4-6) : 275 - 286
  • [9] In vitro assembly of human immunodeficiency virus type 1 Gag protein
    Morikawa, Y
    Goto, T
    Sano, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (39) : 27997 - 28002
  • [10] Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines
    Megede, JZ
    Otten, GR
    Doe, B
    Liu, H
    Srivastava, R
    Greer, C
    Legg, H
    Tang, T
    Polo, JM
    Donnelly, JJ
    Ulmer, JB
    Barnett, SW
    VACCINE, 2006, 24 (15) : 2755 - 2763